Y
Yevhen Hotko
Researcher at Uzhhorod National University
Publications - 24
Citations - 1987
Yevhen Hotko is an academic researcher from Uzhhorod National University. The author has contributed to research in topics: FOLFIRI & Panitumumab. The author has an hindex of 14, co-authored 21 publications receiving 1830 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Valentina Tzekova,Simon Collins,Kelly S. Oliner,Alan Rong,Jennifer Gansert +19 more
TL;DR: Panitumumab plus FOLFIRI significantly improved PFS and is well-tolerated as second-line treatment in patients with WT KRAS mCRC.
Journal ArticleDOI
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
Kenneth J. O'Byrne,Ulrich Gatzemeier,Igor Bondarenko,Carlos H. Barrios,Corinna Eschbach,Uwe M. Martens,Yevhen Hotko,Cornelius Kortsik,Luis Paz-Ares,José Rodrigues Pereira,Joachim von Pawel,Rodryg Ramlau,Jae Kyung Roh,Chih Teng Yu,Christopher Stroh,Ilhan Celik,Armin Schueler,Robert Pirker +17 more
TL;DR: The FLEX study as discussed by the authors showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival in the first-line treatment of EGFRexpressing, advanced non-small-cell lung cancer (NSCLC).
Journal ArticleDOI
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
Marc Peeters,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,C.J.A. Punt,Andrew Strickland,G. Wilson,Tudor-Eliade Ciuleanu,Lynda D. Roman,E. Van Cutsem,Ying Tian,Roger Sidhu +16 more
TL;DR: Primary efficacy and safety findings of this trial support panitumumab-FOLFIRI as a second-line treatment of WT KRAS mCRC and support the known toxicities with anti-epidermal growth factor receptor therapy.
Journal ArticleDOI
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Pei He,Hua Yu,Reija Koukakis,Jan Henrik Terwey,A.S. Jung,Roger Sidhu,Scott D. Patterson +22 more
TL;DR: Findings support RAS testing for patients with mCRC and the benefit–risk of panitumumab–FOLFIRI was improved in the wild-type RAS population compared with theWild-type KRAS exon 2 population.
Journal ArticleDOI
Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
Mary O'Brien,Mark A. Socinski,Alexander Y. Popovich,Igor Bondarenko,Antoaneta Tomova,Borys T. Bilynsky˘ı,Yevhen Hotko,Valentin L. Ganul,Ippolit Y. Kostinsky,Amy J. Eisenfeld,Larissa Sandalic,Fred B. Oldham,B. Bandstra,Alan B. Sandler,Jack W. Singer +14 more
TL;DR: Single-agent PPX, dosed at 175 mg/m2, is active and well tolerated in PS 2 patients with advanced NSCLC and required fewer red blood cell transfusions, hematopoietic growth factors, opioid analgesics, and clinic visits than patients receiving gemcitabine or vinorelbine.